Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05794581 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
A Phase 1 study, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05794581 is a Phase 1 study that has completed, run by Carmot Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT05794581, a Phase 1 study, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
Interventions
- DRUG Placebo
- DRUG CT-868
- DRUG Victoza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2024-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05794581
The ClinicalTrials.gov registry entry for NCT05794581 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carmot Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05794581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05794581 about?
NCT05794581 is a clinical study titled "A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes". This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.
What is the current status of trial NCT05794581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2023-03-21. Estimated completion is 2024-04-06.
What interventions are being tested in trial NCT05794581?
The interventions under investigation include: Placebo (DRUG), CT-868 (DRUG), Victoza (DRUG).
Who is sponsoring clinical trial NCT05794581?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.